Angiotech Pharmaceuticals and Genzyme Corporation Form Collaboration to Develop Innovative Surgical Oncology Treatments
Angiotech Pharmaceuticals, Inc. and Genzyme Corporation announced that they have entered into a strategic collaboration agreement designed to identify, develop and commercialize innovative therapies for cancer patients undergoing surgical removal of tumors.
Angiotech and Genzyme will collaborate to create novel, localized treatments that target the prevention of tumor re-growth after surgery through the direct application of a combined biomaterial/anti-cancer therapeutic at the site of tumor excision. Such products may also be useful in treating inoperable tumors, reducing local tumor side-effects, and improving surgical outcomes while complementing existing systemic therapies.
Under the collaboration agreement, Angiotech and Genzyme will contribute their respective expertise in drug screening and development, cell biology, biomaterials and oncology - along with their respective clinical and commercial infrastructures - to develop products for surgical oncologists and their patients.
The companies will conduct research jointly, with each contributing key personnel, technology and intellectual property. Genzyme will have primary responsibility for clinical development, manufacturing and worldwide commercialization of any collaboration products. Angiotech will participate in the development of products and will have a co-marketing option. Collaboration costs and any eventual profits will be shared equally.
Angiotech Pharmaceuticals, Inc. announced that its shareholders and Board of Directors have approved changes to the Company's executive management team and Board of Directors.
Effective October 8 , Thomas Bailey and Angiotech mutually agreed that Mr. Bailey would transition from his curren ... more
Angiotech Pharmaceuticals, Inc. and partner Athersys, Inc. announced updated results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. T ... more
Angiotech Pharmaceuticals, Inc. announced positive clinical study results for its Bio-Seal(TM) Lung Biopsy Tract Plug System at the Society of Interventional Radiologists Annual Scientific Meeting in San Diego, CA. The trial assessed the safety and efficacy of Bio-Seal in patients undergoin ... more
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical inter ... more
Sanofi Genzyme , the specialty care global business unit of Sanofi, announced a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). T ... more
Genzyme, a Sanofi company, announced that the first pediatric patient has begun treatment in a Phase 1/2 clinical trial focused on evaluating the investigational therapy olipudase alfa. Olipudase alfa is an enzyme replacement therapy being studied for the treatment of nonneurological manife ... more
Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. This enzyme replacement therapy is being investigated for the treatment of patients with nonneurological manifestations of acid ... more